SCT800
Phase 3Biologic
SCT800 is one of 36 biologic programs targeting Hemophilia A. It is currently in Phase 3.
1
Indications
4
Total Trials
2
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
93 competitors in Hemophilia a
#DrugCompanyPhaseTrials
1Hemlibra
RochePhase 3
Recombinant Human Coagulation FVIII
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
Eptacog Alfa
Novo NordiskPhase 3
Qfitlia
GGenzyme, a Sanofi Company
Phase 3
Valoctocogene Roxaparvovec
BioMarin PharmaceuticalPhase 3
Recombinant Factor VIII
BayerPhase 3
Translarna
PPTC Therapeutics
Phase 2
PF-06741086
PfizerPhase 3
Marstacimab
PfizerPhase 3
Rfviia
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hemophilia A4 trials
ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 4·NCT05888870·50 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SCT800. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- SSinocelltech Ltd.